Coronavirus Notebook: WHO Adds More Drugs To Solidarity Trial, COVAX Ups Vaccine Supplies To Africa
The Coalition for Epidemic Preparedness and Innovations is working with China’s ZerunBio to develop prototype and variant vaccine candidates, and Australia believes MSD’s molnupiravir could be a potential treatment for COVID-19. The European Medicines Agency is looking into more possible side effects with two mRNA vaccines.
You may also be interested in...
Coronavirus Notebook: Australia OKs GSK’s Sotrovimab For COVID-19, Iran Takes SpikoGen Vaccine Into Phase III
Bavarian Nordic is testing the potential of its ABNCoV2 vaccine as a booster dose for people with previous infection or vaccination. Brazil has received requests from Pfizer/BioNTech and AstraZeneca to trial vaccines as booster doses, and has asked for more immunogenicity data on SinoVac’s CoronaVac.
Company is ‘anxious to understand’ how to utilize the agency’s views on importance of biomarkers, exec notes in earnings call. Merck & Co. and Pfizer advance COVID-19 therapeutics into Phase III. Pfizer is awaiting FDA risk-benefit assessment of JAK-1 inhibitors Xeljanz and abrocitinib.
Despite an alarming surge in coronavirus cases across the African continent, there are hopes of a substantial rise in vaccine supplies in the coming months.